Gliclazide impurity F: N-[(perhydro­cyclo­penta­[c]pyrrol-2-yl)amino­carbon­yl]-o-toluene­sulfonamide

The title compound, C(15)H(21)N(3)O(3)S, is known to be an impurity of gliclazide [systematic name: N-(hexa­hydro-1H-cyclopenta[c]pyrrol-2-ylcarbamo­yl)-4-methyl­benzene­sulfonamide], a sul­fonyl­urea anti­diabetic drug. Gliclazide has a p-tolyl group substituting the sulfonamide functionality, whil...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Di, Wang, Xueyuan, Pang, Dongying, Su, Wei, Sun, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union of Crystallography 2012
Materias:
Organic Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275201/
https://www.ncbi.nlm.nih.gov/pubmed/22347057
http://dx.doi.org/10.1107/S1600536811054985
_version_ 1782223184179757056
author Wu, Di
Wang, Xueyuan
Pang, Dongying
Su, Wei
Sun, Yan
author_facet Wu, Di
Wang, Xueyuan
Pang, Dongying
Su, Wei
Sun, Yan
author_sort Wu, Di
collection PubMed
description The title compound, C(15)H(21)N(3)O(3)S, is known to be an impurity of gliclazide [systematic name: N-(hexa­hydro-1H-cyclopenta[c]pyrrol-2-ylcarbamo­yl)-4-methyl­benzene­sulfonamide], a sul­fonyl­urea anti­diabetic drug. Gliclazide has a p-tolyl group substituting the sulfonamide functionality, while the title mol­ecule contains an o-tolyl group. Both five-membered fused rings adopt envelope conformations. In the crystal, N—H⋯O hydrogen bonds are formed between HN(C=O)NH groups, building centrosymmetric dimers. These dimers are further linked through N—H⋯O(sulfon­yl) contacts, forming chains in [100].
format Online
Article
Text
id pubmed-3275201
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher International Union of Crystallography
record_format MEDLINE/PubMed
spelling pubmed-32752012012-02-15 Gliclazide impurity F: N-[(perhydro­cyclo­penta­[c]pyrrol-2-yl)amino­carbon­yl]-o-toluene­sulfonamide Wu, Di Wang, Xueyuan Pang, Dongying Su, Wei Sun, Yan Acta Crystallogr Sect E Struct Rep Online Organic Papers The title compound, C(15)H(21)N(3)O(3)S, is known to be an impurity of gliclazide [systematic name: N-(hexa­hydro-1H-cyclopenta[c]pyrrol-2-ylcarbamo­yl)-4-methyl­benzene­sulfonamide], a sul­fonyl­urea anti­diabetic drug. Gliclazide has a p-tolyl group substituting the sulfonamide functionality, while the title mol­ecule contains an o-tolyl group. Both five-membered fused rings adopt envelope conformations. In the crystal, N—H⋯O hydrogen bonds are formed between HN(C=O)NH groups, building centrosymmetric dimers. These dimers are further linked through N—H⋯O(sulfon­yl) contacts, forming chains in [100]. International Union of Crystallography 2012-01-18 /pmc/articles/PMC3275201/ /pubmed/22347057 http://dx.doi.org/10.1107/S1600536811054985 Text en © Wu et al. 2012 http://creativecommons.org/licenses/by/2.0/uk/ This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.
spellingShingle Organic Papers
Wu, Di
Wang, Xueyuan
Pang, Dongying
Su, Wei
Sun, Yan
Gliclazide impurity F: N-[(perhydro­cyclo­penta­[c]pyrrol-2-yl)amino­carbon­yl]-o-toluene­sulfonamide
title Gliclazide impurity F: N-[(perhydro­cyclo­penta­[c]pyrrol-2-yl)amino­carbon­yl]-o-toluene­sulfonamide
title_full Gliclazide impurity F: N-[(perhydro­cyclo­penta­[c]pyrrol-2-yl)amino­carbon­yl]-o-toluene­sulfonamide
title_fullStr Gliclazide impurity F: N-[(perhydro­cyclo­penta­[c]pyrrol-2-yl)amino­carbon­yl]-o-toluene­sulfonamide
title_full_unstemmed Gliclazide impurity F: N-[(perhydro­cyclo­penta­[c]pyrrol-2-yl)amino­carbon­yl]-o-toluene­sulfonamide
title_short Gliclazide impurity F: N-[(perhydro­cyclo­penta­[c]pyrrol-2-yl)amino­carbon­yl]-o-toluene­sulfonamide
title_sort gliclazide impurity f: n-[(perhydro­cyclo­penta­[c]pyrrol-2-yl)amino­carbon­yl]-o-toluene­sulfonamide
topic Organic Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275201/
https://www.ncbi.nlm.nih.gov/pubmed/22347057
http://dx.doi.org/10.1107/S1600536811054985
work_keys_str_mv AT wudi gliclazideimpurityfnperhydrocyclopentacpyrrol2ylaminocarbonylotoluenesulfonamide
AT wangxueyuan gliclazideimpurityfnperhydrocyclopentacpyrrol2ylaminocarbonylotoluenesulfonamide
AT pangdongying gliclazideimpurityfnperhydrocyclopentacpyrrol2ylaminocarbonylotoluenesulfonamide
AT suwei gliclazideimpurityfnperhydrocyclopentacpyrrol2ylaminocarbonylotoluenesulfonamide
AT sunyan gliclazideimpurityfnperhydrocyclopentacpyrrol2ylaminocarbonylotoluenesulfonamide

Ejemplares similares